239 related articles for article (PubMed ID: 31923062)
21. Sexual functioning in women using levonorgestrel-releasing intrauterine systems as compared to copper intrauterine devices.
Enzlin P; Weyers S; Janssens D; Poppe W; Eelen C; Pazmany E; Elaut E; Amy JJ
J Sex Med; 2012 Apr; 9(4):1065-73. PubMed ID: 21492401
[TBL] [Abstract][Full Text] [Related]
22. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
Bilgehan F; Dilbaz B; Karadag B; Deveci CD
J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
[TBL] [Abstract][Full Text] [Related]
23. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
[TBL] [Abstract][Full Text] [Related]
24. Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study.
Turok DK; Sanders JN; Thompson IS; Royer PA; Eggebroten J; Gawron LM
Contraception; 2016 Jun; 93(6):526-32. PubMed ID: 26944863
[TBL] [Abstract][Full Text] [Related]
25. Profiles of copper intrauterine devices and levonorgestrel intrauterine systems users in France in 2019: A national observational population-based study.
Roland N; Baricault B; Dray-Spira R; Weill A; Duranteau L; Zureik M
Int J Gynaecol Obstet; 2023 Feb; 160(2):594-603. PubMed ID: 36066002
[TBL] [Abstract][Full Text] [Related]
26. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil.
Bahamondes L; Fernandes A; Bahamondes MV; Juliato CT; Ali M; Monteiro I
Contraception; 2018 Mar; 97(3):205-209. PubMed ID: 29055780
[TBL] [Abstract][Full Text] [Related]
27. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
Kakaire O; Tumwesigye NM; Byamugisha JK; Gemzell-Danielsson K
Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):220-6. PubMed ID: 26895345
[TBL] [Abstract][Full Text] [Related]
28. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
Chi IC
Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
[TBL] [Abstract][Full Text] [Related]
30. Intraperitoneal levonorgestrel-releasing intrauterine device following uterine perforation: the role of progestins in adhesion formation.
Haimov-Kochman R; Doviner V; Amsalem H; Prus D; Adoni A; Lavy Y
Hum Reprod; 2003 May; 18(5):990-3. PubMed ID: 12721174
[TBL] [Abstract][Full Text] [Related]
31. Levonorgestrel intrauterine device use and incident idiopathic intracranial hypertension among commercially insured women.
De Lott LB; Moniz MH; Niziol LM; Khanna S; Musch DC; Cornblath WT
Contraception; 2023 Sep; 125():110089. PubMed ID: 37331461
[TBL] [Abstract][Full Text] [Related]
32. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
33. Weight change at 12 months in users of three progestin-only contraceptive methods.
Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
[TBL] [Abstract][Full Text] [Related]
34. Complications and continuation of intrauterine device use among commercially insured teenagers.
Berenson AB; Tan A; Hirth JM; Wilkinson GS
Obstet Gynecol; 2013 May; 121(5):951-958. PubMed ID: 23635730
[TBL] [Abstract][Full Text] [Related]
35. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
36. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
French R; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Guillebaud J
Cochrane Database Syst Rev; 2001; (2):CD001776. PubMed ID: 11406007
[TBL] [Abstract][Full Text] [Related]
37. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
[TBL] [Abstract][Full Text] [Related]
38. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
[TBL] [Abstract][Full Text] [Related]
39. Levonorgestrel levels in serum and uterine flushings in women bearing LNG-Cu-IUD.
Shi JP; Wu XR
J Tongji Med Univ; 1993; 13(2):126-8. PubMed ID: 8230357
[TBL] [Abstract][Full Text] [Related]
40. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
